Current Rating Overview
MarketsMOJO currently assigns Pfizer Ltd. a 'Sell' rating, reflecting a cautious stance on the stock. This rating was established on 29 Dec 2025, when the company’s Mojo Score declined by 12 points from 54 to 42, signalling a shift from a 'Hold' to a 'Sell' recommendation. The Mojo Grade now stands at 42.0, indicating below-average prospects relative to market expectations.
Understanding the Rating Components
The 'Sell' rating is derived from a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of Pfizer Ltd.’s investment appeal as of 22 May 2026.
Quality Assessment
Pfizer Ltd. maintains a good quality grade, reflecting solid operational fundamentals and a respectable return on equity (ROE) of 18.1%. This suggests that the company is effective at generating profits from shareholders’ equity, a positive indicator for long-term investors. However, despite this strength, the company’s growth trajectory has been modest, with net sales increasing at an annual rate of just 2.39% over the past five years. Operating profit growth has been somewhat better at 7.03% annually, but still indicates limited expansion momentum.
Valuation Considerations
Valuation remains a significant concern, with Pfizer Ltd. rated as very expensive. The stock trades at a price-to-book (P/B) ratio of 5.1, which is high relative to typical benchmarks and suggests that investors are paying a premium for the company’s assets. While this valuation is in line with the historical averages of its peers, it raises questions about the stock’s upside potential, especially given the company’s flat financial trend and subdued growth. The price-earnings-to-growth (PEG) ratio stands at 1.4, indicating that the stock’s price growth expectations are somewhat elevated compared to its earnings growth.
Financial Trend Analysis
The financial trend for Pfizer Ltd. is currently flat. The latest quarterly results for March 2026 showed no significant improvement, reflecting a period of stagnation. Despite this, the company’s profits have risen by 19.8% over the past year, a positive sign amid broader challenges. However, this profit growth has not translated into strong stock performance, as the share price has declined by 6.29% over the same period. This divergence suggests that investors remain cautious about the sustainability of earnings growth.
Technical Outlook
From a technical perspective, Pfizer Ltd. is rated as mildly bearish. The stock has experienced negative returns across multiple time frames: a 1-day gain of 0.45% is overshadowed by declines of 5.25% over one week, 1.74% over one month, and 6.44% over six months. Year-to-date, the stock is down 6.08%, and over the past year it has lost 8.82%. Moreover, Pfizer has underperformed the BSE500 index over the last three years, one year, and three months, indicating weaker relative momentum and investor sentiment.
Implications for Investors
For investors, the 'Sell' rating signals caution. While Pfizer Ltd. demonstrates good quality fundamentals and a respectable ROE, its expensive valuation and flat financial trend limit its attractiveness. The mildly bearish technical outlook further suggests that the stock may face continued headwinds in the near term. Investors should carefully weigh these factors against their portfolio objectives and risk tolerance before considering exposure to Pfizer Ltd.
Summary of Key Metrics as of 22 May 2026
Currently, the company’s financial metrics indicate:
- Net sales growth at an annual rate of 2.39% over five years
- Operating profit growth of 7.03% annually over the same period
- Return on equity of 18.1%
- Price-to-book ratio of 5.1, reflecting a very expensive valuation
- Profit growth of 19.8% over the past year
- Stock returns of -8.82% over the last year and -6.08% year-to-date
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Sector and Market Context
Pfizer Ltd. operates within the Pharmaceuticals & Biotechnology sector, a space often characterised by innovation-driven growth and regulatory complexities. Despite the sector’s potential, Pfizer’s recent performance has lagged behind broader market indices such as the BSE500. This underperformance highlights challenges in sustaining competitive advantage and growth momentum amid evolving market dynamics.
Long-Term Growth Challenges
The company’s modest net sales growth of 2.39% annually over five years points to difficulties in expanding its top line significantly. This slow growth may be attributed to competitive pressures, patent expiries, or shifts in product demand. Operating profit growth at 7.03% annually is somewhat more encouraging but still reflects a cautious growth environment. Investors should consider these factors when evaluating Pfizer’s future earnings potential.
Valuation Versus Peers
While Pfizer’s valuation is high, it remains broadly in line with historical averages for its peer group. This suggests that the market continues to price in expectations of steady earnings and potential innovation. However, the elevated price-to-book ratio and PEG ratio of 1.4 imply limited margin for valuation expansion, especially if growth disappoints.
Technical Signals and Market Sentiment
The mildly bearish technical grade reflects recent price weakness and underperformance relative to benchmarks. The stock’s negative returns over multiple time frames indicate investor caution, possibly driven by concerns over growth prospects and valuation. This technical backdrop may weigh on near-term price performance.
Conclusion
In summary, Pfizer Ltd.’s 'Sell' rating by MarketsMOJO as of 29 Dec 2025 is supported by a combination of very expensive valuation, flat financial trends, and a cautious technical outlook, despite the company’s good quality fundamentals. As of 22 May 2026, investors should approach the stock with prudence, recognising the challenges it faces in delivering sustained growth and attractive returns in the current market environment.
53% Discount is LIVE - Get MojoOne + Stock of the Week for 3 Years Start Today
